Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Chuikyo OKs Quantitative Premium Calculation for Operating Profit Rates
March 19, 2015
-
BUSINESS MSD Revving Up Detailing on Rotavirus, Hepatitis B Vaccines, Eyes Public Immunization Program
March 18, 2015
-
ACADEMIA Researcher Has High Hopes for Immunotherapies as Fourth Pillar of Cancer Treatment
March 17, 2015
-
BUSINESS Takecab Surged to Top Spot in January Anterio Ranking
March 16, 2015
-
REGULATORY Prime Minister Abe Indicates the Need to Promote the Use of Biosimilars
March 16, 2015
-
REGULATORY PMDA Plans to Introduce Full Scale “Patient ADR Reporting System” by FY2018
March 13, 2015
-
BUSINESS Takecab vs PPIs (3): Which Will Come Out on Top? Everything Now in the Hands of Frontline Prescribers
March 13, 2015
-
ORGANIZATION JSGM President Calls for Generic Share Target of 80% by FY2020
March 12, 2015
-
BUSINESS Takecab vs PPIs (2): Takecab to Initially Gain Share for H. pylori Eradication?
March 12, 2015
-
BUSINESS AZ to Tap Rich Pipelines to Grow as Oncology Powerhouse
March 11, 2015
-
BUSINESS Takecab vs PPIs (1): “Rapid, Sustained Efficacy” Pitted against “Patient Satisfaction”, Will Paradigm Shift Occur?
March 11, 2015
-
REGULATORY MHLW to Target 75% Generic Share for Welfare Recipients
March 10, 2015
-
ACADEMIA Interview on SGLT-2 Inhibitor Use (2): Prof. Watada Calls for Caution in Analyzing EPPV Data
March 9, 2015
-
ACADEMIA Interview on SGLT-2 Inhibitor Use (1): Prof. Ueki Says Flat Sales Reflect Cautious Prescribing by Physicians
March 6, 2015
-
BUSINESS Pfizer Japan Sales Down 5% as Generic Erosion Weighs
March 5, 2015
-
BUSINESS Weber to Become CEO of Takeda in April
March 4, 2015
-
REGULATORY Pharma Might Skirt Market-Price Based Price Cuts in 2017 If Physician Fees Become Taxable
March 3, 2015
-
BUSINESS Eli Lilly Aims to Lead Japan Diabetes Market by 2020
March 2, 2015
-
REGULATORY Novartis Slapped with 15 Day Biz Suspension over Flawed ADR Reporting
February 27, 2015
-
ACADEMIA Govt-Backed Research Center Looks to License Malaria Vaccine to Mega Pharma
February 27, 2015
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…